PriceTargets.com logo

Akero Therapeutics - AKRO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $43.20
  • Forecasted Upside: 45.16%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$29.76 As of 11/14/2024 01:00 AM ET
▼ -1.21 (-3.91%)

This chart shows the closing price for AKRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akero Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKRO

Analyst Price Target is $43.20
▲ +45.16% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Akero Therapeutics in the last 3 months. The average price target is $43.20, with a high forecast of $56.00 and a low forecast of $30.00. The average price target represents a 45.16% upside from the last price of $29.76.

This chart shows the closing price for AKRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Akero Therapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/12/2024Cantor FitzgeraldReiterated RatingOverweight
6/11/2024Wolfe ResearchInitiated CoverageOutperform
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/15/2024Evercore ISILower TargetOutperform ➝ Outperform$50.00 ➝ $38.00
5/13/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$59.00 ➝ $56.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/22/2024Bank of AmericaInitiated CoverageNeutral$30.00
3/5/2024UBS GroupBoost TargetBuy ➝ Buy$39.00 ➝ $42.00
3/1/2024HC WainwrightBoost TargetBuy ➝ Buy$40.00 ➝ $43.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$40.00
10/12/2023UBS GroupLower TargetBuy ➝ Buy$83.00 ➝ $39.00
10/11/2023HC WainwrightLower TargetBuy ➝ Buy$64.00 ➝ $40.00
10/11/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$69.00 ➝ $39.00
10/11/2023Morgan StanleyLower TargetOverweight ➝ Overweight$70.00 ➝ $33.00
10/11/2023Evercore ISILower Target$60.00 ➝ $36.00
10/11/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$62.00 ➝ $41.00
10/4/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$69.00
9/19/2023Cantor FitzgeraldInitiated CoverageOverweight$69.00
9/13/2023Evercore ISIBoost TargetOutperform ➝ Outperform$50.00 ➝ $60.00
9/5/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$49.00 ➝ $62.00
8/28/2023UBS GroupInitiated CoverageBuy$83.00
6/7/2023HC WainwrightBoost Target$62.00 ➝ $64.00
5/16/2023HC WainwrightLower Target$64.00 ➝ $62.00
4/11/2023Lifesci CapitalReiterated RatingOutperform
3/21/2023Canaccord Genuity GroupBoost TargetBuy$50.00 ➝ $58.00
1/27/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$40.00 ➝ $65.00
11/7/2022Morgan StanleyBoost TargetEqual Weight$30.00 ➝ $40.00
11/7/2022HC WainwrightBoost TargetBuy$62.00 ➝ $64.00
9/14/2022Morgan StanleyBoost TargetEqual Weight$26.00 ➝ $30.00
9/13/2022Evercore ISIUpgradeIn-Line ➝ Outperform$10.00 ➝ $50.00
9/13/2022Raymond JamesBoost Target$14.00 ➝ $25.00
11/15/2021Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $29.00
11/15/2021HC WainwrightLower TargetBuy$64.00 ➝ $62.00
10/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$27.00
9/10/2021Bank of AmericaInitiated CoverageBuy$40.00
8/16/2021HC WainwrightLower TargetBuy$68.00 ➝ $64.00
3/23/2021Jefferies Financial GroupReiterated RatingBuy$48.00
3/23/2021Morgan StanleyLower TargetOverweight$70.00 ➝ $63.00
3/23/2021HC WainwrightBoost TargetPositive ➝ Buy$61.00 ➝ $68.00
3/17/2021HC WainwrightLower TargetBuy$64.00 ➝ $61.00
3/17/2021Chardan CapitalBoost TargetPositive ➝ Buy$79.00 ➝ $81.00
2/26/2021GuggenheimInitiated CoverageBuy$54.00
11/13/2020HC WainwrightBoost TargetBuy$62.00 ➝ $64.00
9/10/2020Morgan StanleyInitiated CoverageOverweight$70.00
8/13/2020Chardan CapitalReiterated RatingBuy
7/20/2020HC WainwrightBoost TargetBuy$45.00 ➝ $62.00
7/7/2020Chardan CapitalInitiated CoverageBuy$79.00
7/1/2020JPMorgan Chase & Co.Boost TargetOverweight$28.00 ➝ $41.00
7/1/2020Jefferies Financial GroupBoost TargetBuy$31.00 ➝ $48.00
7/1/2020HC WainwrightBoost TargetBuy$33.00 ➝ $45.00
3/2/2020HC WainwrightInitiated CoverageBuy$33.00
(Data available from 11/15/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 7 very positive mentions
  • 57 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/19/2024
  • 13 very positive mentions
  • 64 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2024
  • 3 very positive mentions
  • 32 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2024
  • 14 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2024
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2024
  • 12 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2024
  • 14 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2024

Current Sentiment

  • 14 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $29.76
Low: $29.58
High: $31.43

50 Day Range

MA: $29.36
Low: $25.62
High: $35.28

52 Week Range

Now: $29.76
Low: $13.86
High: $37.00

Volume

720,228 shs

Average Volume

866,186 shs

Market Capitalization

$2.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Akero Therapeutics?

The following Wall Street analysts have issued reports on Akero Therapeutics in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., Cantor Fitzgerald, Evercore ISI, HC Wainwright, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for AKRO.

What is the current price target for Akero Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Akero Therapeutics in the last year. Their average twelve-month price target is $43.20, suggesting a possible upside of 45.2%. Canaccord Genuity Group Inc. has the highest price target set, predicting AKRO will reach $56.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $30.00 for Akero Therapeutics in the next year.
View the latest price targets for AKRO.

What is the current consensus analyst rating for Akero Therapeutics?

Akero Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AKRO.

What other companies compete with Akero Therapeutics?

Other companies that are similar to Akero Therapeutics include Albireo Pharma, CymaBay Therapeutics, Enanta Pharmaceuticals, Roivant Sciences and Ascendis Pharma A/S. Learn More about companies similar to Akero Therapeutics.

How do I contact Akero Therapeutics' investor relations team?

Akero Therapeutics' physical mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 487-6488 and its investor relations email address is [email protected]. The official website for Akero Therapeutics is www.akerotx.com. Learn More about contacing Akero Therapeutics investor relations.